Significant disease-free survival for patients diagnosed with non-small cell lung cancer, clinical trial finds
New data from a clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC).
Materials provided by Yale University. Original written by Michael Masciadrelli. Note: Content may be edited for style and length.
Source link aaaaa